Three-year data from a trial of 30 patients implanted with a bioabsorbable, drug-eluting coronary stent from Abbott are showing the promise of this alternative stent technology, according to a press release from the company.
Abbott’s bioabsorbable coronary stent is an everolimus-coated coronary scaffold is made of polylactide, the same material used in absorbable sutures. According to Medgadget and an Abbott press release:
The ABSORB trial is a prospective, non-randomized (open label), two-phase study designed to enroll approximately 130 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key endpoints of the study include assessments of safety – MACE and stent thrombosis rates – at 30 days; six, nine, 12 and 18 months; and two years, with additional annual clinical follow-up for up to five years, as well as an assessment of the acute performance of the bioabsorbable drug eluting stent, including successful deployment of the system. Other key endpoints of the study include imaging assessments by angiography, intravascular ultrasound (IVUS), optical coherence tomography (OCT), and other state-of-the-art invasive and non-invasive imaging modalities at six months, one year and two years.
The $7.4 billion global coronary stent market is dominated by $4.7 billion in drug-eluting stent sales, but as bioabsorbable stents emerge and are introduced to the market, expected as early as 2012, the market is expected to shift toward bioabsorable stents, which will putatively minimize long(er) term risks like late stage thrombosis.
MedMarket Diligence has published its report, “Worldwide Coronary Stents, 2008-2017”, report #C245.
Posted via web from medmarket’s posterous
More from advanced medtech blog...